---
layout: default
title: Carfilzomib
parent: 僅模型預測 (L5)
nav_order: 90
evidence_level: L5
indication_count: 5
---

# Carfilzomib
{: .fs-9 }

證據等級: **L5** | 預測適應症: **5** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

# Carfilzomib: From Multiple Myeloma to CMM7

## One-Sentence Summary

Carfilzomib is a second-generation proteasome inhibitor; literature within this evidence pack identifies it as a frontline anti-myeloma agent, though no structured original-indication data was returned for this drug.
The TxGNN model predicts it may be effective for **CMM7** (familial cutaneous malignant melanoma type 7), but this is currently a **pure model prediction with 0 clinical trials and 0 publications** specifically supporting it.
Given the complete absence of direct evidence, this candidate sits at evidence level **L5** and the recommended decision is **Hold**.

---

## Quick Overview

| Item | Content |
|------|------|
| Original Indication | Multiple Myeloma *(inferred from literature context in this pack; not present in structured indication/license fields)* |
| Predicted New Indication | CMM7 (familial cutaneous malignant melanoma type 7) |
| TxGNN Prediction Score | 99.37% |
| Evidence Level | L5 |
| Finland Market Status | ✗ Not Marketed |
| Number of Authorizations | 0 |
| Recommended Decision | Hold |

---

## Why is This Prediction Reasonable?

Currently, no structured mechanism-of-action data is recorded for carfilzomib in this evidence pack (`original_moa: [Data Gap]`). However, contextual information elsewhere in the pack describes carfilzomib as a second-generation, irreversible proteasome inhibitor that blocks the chymotrypsin-like activity of the 26S proteasome, causing accumulation of misfolded proteins, NF-κB pathway dysregulation, and apoptosis — a mechanism established in the treatment of multiple myeloma.

For the CMM7 prediction specifically, the model's own rationale states there is **no known direct mechanistic link** between carfilzomib's proteasome-inhibition pathway and CMM7, a familial melanoma subtype most associated with germline POT1 and other telomere/DNA-repair gene variants. This prediction appears to be a broad extrapolation from the general "melanoma" disease category rather than a CMM7-specific signal.

Separately (not part of this specific candidate), this evidence pack does contain preclinical literature on carfilzomib in melanoma more generally — five papers, mostly cell-line and in-silico studies, showing pro-apoptotic effects in B16-F1 melanoma cells and molecular-docking activity against melanoma-relevant kinases. None of this literature addresses CMM7 or its POT1-driven biology, so it does not directly strengthen the present prediction, but it does indicate the broader "melanoma" category is not entirely mechanistically unexplored for this drug.

---

## Clinical Trial Evidence

Currently no related clinical trials registered.

---

## Literature Evidence

Currently no related literature available.

---

## Finland Market Information

Carfilzomib is currently not marketed in Finland; no authorization records exist in the evidence pack.

---

## Cytotoxicity

| Item | Content |
|------|------|
| Cytotoxicity Classification | Targeted therapy (proteasome inhibitor) |
| Myelosuppression Risk | Please refer to the package insert warnings and precautions |
| Emetogenicity Classification | Please refer to the package insert warnings and precautions |
| Monitoring Items | Please refer to the package insert warnings and precautions |
| Handling Protection | Please refer to the package insert warnings and precautions |

---

## Safety Considerations

Please refer to the package insert for safety information.

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
The CMM7 prediction is supported only by a TxGNN model score (L5, S0) with zero clinical trials and zero publications, and the mechanistic rationale itself confirms no known link between carfilzomib's proteasome-inhibition pathway and CMM7's POT1/telomere-driven biology. There is no evidence basis to advance this candidate at this time.

**To proceed, the following is needed:**
- TFDA/manufacturer package insert (warnings, contraindications) — currently a Blocking data gap (DG001)
- Formal, structured mechanism-of-action data from DrugBank or equivalent (DG002)
- Preclinical or mechanistic studies directly linking proteasome inhibition to POT1-mutant/CMM7 melanoma biology
- Any real-world or observational signal (even off-label) connecting carfilzomib to familial melanoma subtypes
- Finland market/regulatory pathway assessment, given the drug is not currently marketed there
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

